Phillip Chan Email and Phone Number
Phillip Chan work email
- Valid
- Valid
- Valid
- Valid
Phillip Chan personal email
Phillip Chan phone numbers
Phillip Chan is a Chief Executive Officer at CytoSorbents Corporation at CytoSorbents Corporation. Colleagues describe him as "I have worked with Phil on several investment transactions. Phil is a seasoned VC who knows how to work with companies and advisors to close complex deals quickly and precisely."
-
Chief Executive OfficerCytosorbents Corporation Jan 2009 - PresentPrinceton, New Jersey, UsCytoSorbents (NASDAQ: CTSO) is a publicly-traded, critical care immunotherapy company using blood purification to control cytokine storm and hyperinflammation in deadly diseases such as sepsis, COVID-19 (under U.S. FDA Emergency Use Authorization), burns, trauma, ARDS, and cytokine release syndrome. The Company's flagship product, CytoSorb®, is a highly efficient cytokine adsorber approved in the European Union to fight cytokine storm in critical illnesses that could otherwise cause massive inflammation and organ failure, the leading cause of death in the ICU. CytoSorb is also being used during open heart surgery to remove free hemoglobin and other inflammatory mediators that can cause post-op inflammation and organ damage. CytoSorb is also E.U. approved to remove the anti-thrombotic agents, ticagrelor (Brilinta) and rivaroxaban (Xarelto) during on-pump cardiothoracic surgery. In the U.S. and Canada, the pivotal STAR-T RCT is expected to complete in 2023 and support FDA and Health Canada marketing approval of DrugSorb-ATR for Brilinta removal under FDA Breakthrough Designation. With E.U. regulatory approval for CytoSorb, ISO 13485 manufacturing in NJ, reimbursement and a direct sales force in Germany, distribution in 75 countries worldwide, strategic partnerships with Fresenius Medical Care, B Braun, Biocon, Terumo Cardiovascular, and a hardware agreement with Nikkiso, and 2022 total revenue of $34.7M, CytoSorbents is an exciting emerging growth company that is helping to save lives and to reduce the exorbitant costs of ICU care. The technology has received ~$48M in support from DARPA, NIH, US Army, Air Force, HHS and others. This adds to a significant internal R&D effort that has resulted in promising development stage products such as HemoDefend-RBC (pRBC) and HemoDefend-BGA (plasma) for blood transfusions, K+ontrol (hyperkalemia), CytoSorb XL, DrugSorb (drug overdose), and ContrastSorb (contrast-induced nephropathy).
-
PartnerNjtc Venture Fund Jan 2007 - Dec 2008
-
AssociateNjtc Venture Fund 2003 - 2006
Phillip Chan Education Details
-
Harvard Medical SchoolInternal Medicine Residency - Beth Israel Deaconess Medical Center -
Yale School Of MedicineMedicine And Genetics
-
Cornell UniversityCell And Molecular Biology
Frequently Asked Questions about Phillip Chan
What company does Phillip Chan work for?
Phillip Chan works for Cytosorbents Corporation
What is Phillip Chan's role at the current company?
Phillip Chan's current role is Chief Executive Officer at CytoSorbents Corporation.
What is Phillip Chan's email address?
Phillip Chan's email address is ph****@****cvc.com
What is Phillip Chan's direct phone number?
Phillip Chan's direct phone number is +173232*****
What schools did Phillip Chan attend?
Phillip Chan attended Harvard Medical School, Yale School Of Medicine, Cornell University.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial